Development of a novel and direct peptide Helicon™ inhibitor of ß-catenin-TCF interaction with in vivo validation of transcriptional modulation and anti-tumor activity

被引：0

作者：

Si, Yaguang ^{[1
]}

White, Brian ^{[1
]}

Cappucci, Sarah ^{[1
]}

Ramirez, Jessica ^{[1
]}

Ponthier, Charles ^{[1
]}

Visness, Erica ^{[1
]}

Ling, Kevin ^{[1
]}

Du, Peicheng ^{[1
]}

Choi, Minjung ^{[1
]}

Thomson, Ty ^{[1
]}

Alfaro-Lopez, Josue ^{[1
]}

Beerepoot, Pieter ^{[1
]}

Agarwal, Sorabh ^{[1
]}

Ortet, Paula ^{[1
]}

Lech, Miroslaw ^{[1
]}

Li, Zhi ^{[2
]}

Olokpa, Voke ^{[3
]}

Jewett, Ivan ^{[4
]}

La, Daniel ^{[5
]}

Yu, Lihua ^{[1
]}

McGee, John ^{[1
]}

Tremblay, Martin ^{[1
]}

Hurov, Jonathan ^{[1
]}

Verdine, Greg ^{[1
]}

机构：

[1] FogPharma, Cambridge, MA USA

[2] Georgetown Univ, Washington, DC USA

[3] Ikena Oncol, Cambridge, MA USA

[4] Black Diamond Therapeut, Cambridge, MA USA

[5] Santi Therapeut, Cambridge, MA USA

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

345

引用

下载

页数：2

共 25 条

[21] DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080
Foxiao Qiao
Daiying Zuo
Xueqi Shen
Huan Qi
Haifeng Wang
Weige Zhang
Yingliang Wu
Cancer Chemotherapy and Pharmacology, 2012, 70 : 259 - 270
[22] DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080
Qiao, Foxiao
Zuo, Daiying
Shen, Xueqi
Qi, Huan
Wang, Haifeng
Zhang, Weige
Wu, Yingliang
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 259 - 270
[23] Metformin Affects the Proliferation Cell Nuclear Antigen (PCNA) and p21 Protein Interaction Resulting in Direct Anti-Tumor Activity and Enhances the Cytotoxic/Biological Effects of Chemotherapy Agents or Rituximab in Lymphoma in Vitro and in Vivo Pre-Clinical Models
Gu, Juan J.
Yanamadala, Vivek
Singh, Anil
Mavis, Cory
Czuczman, Myron S.
Hernandez, Francisco
BLOOD, 2014, 124 (21)
[24] Combination Therapy of the Novel PI3K Inhibitor GDC-0941 and Dual PI3K/mTOR Inhibitor GDC-0980 with Trastuzumab-DM1 Antibody Drug Conjugate Enhances Anti-Tumor Activity in Preclinical Breast Cancer Models In Vitro and In Vivo
Sampath, D.
Fields, C.
Li, G.
Prior, W. W.
Parsons, K.
Friedman, L. S.
Lewis-Phillips, G. D.
CANCER RESEARCH, 2010, 70
[25] Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.
Sampath, Deepak
Herter, Sylvia
Ingalla, Ellen
Herting, Frank
Bacac, Marina
Nannini, Michelle
Fairbrother, Wayne J.
Klein, Christian
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)

← 1 2 3 →